Dragonboat Biopharmaceutical Company Limited

This study is testing an investigational drug called BC006 in people with idiopathic pulmonary fibrosis (IPF), a serious lung scarring disease. Over 24 weeks, researchers will compare BC006 against a placebo in 96 participants to see if it can help slow the decline in lung functi…